Market Intelligence, Clinical Progress, and High-Purity Reagents for Ophthalmology and Rare Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HTRA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HTRA1 Recombinant Protein (Active Trimer) HEK293 expressed, native glycosylation. High purity (>95%), endotoxin controlled (<1.0 EU/μg). Sequence verified. Suitable for enzymatic assays and SPR binding. |
View HTRA1 Products |
| Gene Delivery | HTRA1 Lentivirus Premade Particles Full-length human HTRA1 ORF for stable cell line construction and functional overexpression assays. |
View HTRA1 Products |
| Benchmark Ab | Anti-HTRA1 Recombinant Antibody (Galegenimab Biosimilar) Recombinant monoclonal antibody utilizing the variable region sequence of clinical benchmark Galegenimab. Positive control for ligand blocking and neutralization assays. |
View HTRA1 Products |
| Validator | HTRA1 siRNA Set Target-specific siRNA pool for target validation and knockdown assays in primary human RPE cells. |
View HTRA1 Products |
| Related Target A | HTRA2 Mitochondrial serine protease. Essential counter-screening target to evaluate the selectivity of small molecule and biologic HTRA1 inhibitors. |
View HTRA2 Products |
| Related Target B | TGFB1 HTRA1 regulates TGF-β signaling via cleavage of latent TGF-β binding proteins. Crucial for downstream pathway validation. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protease Activity Preservation | Active trimeric HTRA1 recombinant protein produced in mammalian HEK293 cells, preserving critical post-translational modifications and self-cleavage control. |
| Family Selectivity Screening | High-purity recombinant proteins for homologous family members (HTRA2, HTRA3, HTRA4) to confirm off-target profiles. |
| Lack of Controls | Inclusion of clinical-grade benchmark antibody biosimilars (Galegenimab sequence) for assay calibration. |
| False Positives | Sequence-verified siRNA sets included to confirm target-specific knockdown and biological phenotypes. |
Live HTRA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HTRA1 therapeutics is intensifying, with major players shifting focus from traditional systemic mAbs to highly localized intravitreal therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting sustained-release formulations and gene therapy modalities to overcome the challenges of frequent intravitreal injections.
HTRA1 is recognized as a key genetic risk factor and driver of Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD). Genetic variations in the HTRA1 promoter lead to its overexpression, resulting in degradation of the extracellular matrix and Bruch's membrane. Inhibiting HTRA1 protease activity represents a major therapeutic approach to slowing down the progression of geographic atrophy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody / Fab | Roche (Genentech) | Geographic Atrophy, AMD | Functional inhibition assays requiring highly active, trimeric recombinant HTRA1 antigen. |
| Gene Therapy | Takeda (Shire) | CARASIL, Ophthalmic Diseases | Stable cell lines generated via lentiviral transduction to validate intracellular protease expression and processing. |
| Small Molecule Inhibitors | Academic Spin-offs, Biotech | Neovascular AMD, Oncology | High-throughput screening assays utilizing purified catalytic domains and selectivity panels (HTRA2/3/4). |